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ABSTRACT
Aim To assess the efﬁcacy of pegaptanib as maintenance
therapy in neovascular age-related macular degeneration
(NV-AMD) patients after induction therapy.
Methods A phase IV, prospective, open-label,
uncontrolled exploratory study including subjects with
subfoveal NV-AMD who had had one to three induction
treatments 30e120 days before entry and showed
investigator-determined clinical/anatomical NV-AMD
improvement. Lesions in the study eye were: any
subtype, 12 or fewer disc areas; postinduction centre
point thickness (CPT) 275 mm or less or thinning of
100 mm or more (optical coherence tomography); visual
acuity (VA) 20/20e20/400. Intravitreal pegaptanib
0.3 mg was administered as maintenance every 6 weeks
for 48 weeks with follow-up to week 54. Booster
treatment additional unscheduled treatment for wet age-
related macular degeneration, was allowed in the study
eye at the investigators’ discretion for clinical
deterioration.
Results Of 568 enrolled subjects, 86% completed
1 year of pegaptanib. Mean VA improvement during
induction (49.6 to 65.5 letters) was well preserved
(54-week mean 61.8 letters). Mean CPT was relatively
stable during maintenance (20 mm increase during the
study). Fifty per cent did not receive unscheduled
booster treatment to week 54; 46% did have one
such booster (mean 147 days after maintenance
initiation).
Conclusions An induction-maintenance strategy, using
non-selective then selective vascular endothelial growth
factor (VEGF) inhibitors, could be considered for NV-
AMD. This approach may have particular relevance for
patients with systemic comorbidities who require long-
term anti-VEGF therapy for NV-AMD.
Treatment of neovascular age-related macular
degeneration (NV-AMD) has changed dramatically
in the past 5 years with the clinical use of intra-
vitreal agents speciﬁcally targeting vascular endo-
thelial growth factor (VEGF). This development,
the culmination of more than a decade of work into
the pathophysiology of NV-AMD, led to the
approval of two drugs as intravitreal therapies:
pegaptanib sodium, an RNA aptamer targeting
VEGF165,
1 and ranibizumab, a monoclonal anti-
body fragment that binds all VEGF isoforms.
23In
addition, bevacizumab, a monoclonal antibody
related to ranibizumab that also binds all VEGF
isoforms, has been used off-label extensively to
treat a variety of ocular neovascular conditions.
4
The optimal utilisation of these agents remains
a matter of debate. In pivotal trials, ranibizumab
provided a signiﬁcant improvement in mean visual
acuity (VA) compared with control groups in NV-
AMD patients.
2 3 It has been suggested that these
results may be attributed to its mechanism of action
in binding all VEGF isoforms.
5 However, the
systemic safety of pan-VEGF agents still concerns
some practitioners, and the use of the non-selective
VEGF antagonist, bevacizumab, in cancer chemo-
therapeutic regimens has been associated with an
increased incidence of hypertension, bleeding and
thromboembolic events.
6 Whereas the doses
employedwithintravitreal administration aremuch
lower, systemic exposure is likely given that the
aberrant vasculature tends to be particularly leaky.
This safety concern is relevant to the NV-AMD
patient who is already at increased risk of hyper-
tension,strokeandcardiovasculardisease
7and,thus,
is at greater risk of treatment-related systemic
complications, especially because anti-VEGF thera-
pies are generally used on a long-term basis.
Pegaptanib has been used in clinical studies for
more than 4 years without the appearance of
systemic or ocular safety signals
8 9 and has also
been examined at doses 10 times greater than those
employed clinically without any evidence of an
increased risk of systemic adverse effects.
10 Its
positive safety proﬁle has led to attempts to
combine both the efﬁcacy of non-speciﬁc inhibi-
tion with the apparent safety of pegaptanib. In
small-scale studies, an initial inductive dose of a
non-speciﬁc VEGF inhibitor was followed by main-
tenance therapy with pegaptanib and booster doses
of pegaptanib as required.
11 12 Because these studies
reported encouraging results, the present explor-
atory study (Evaluation of Efﬁcacy and Safety
in Maintaining Visual Acuity with Sequential
Treatment of Neovascular AMD; LEVEL) was
undertaken as a larger scale application of this
fundamental methodology. In this study, the safety
and efﬁcacy of pegaptanib maintenance in patients
with NV-AMD who experienced a clinical
improvement in disease following an induction
phase were assessed.
MATERIALS AND METHODS
The protocol for this phase IV, prospective, open-
label, uncontrolled exploratory study was reviewed
and approved by an institutional review board at
each study site in accordance with the guidelines
for the conduct of clinical research in the 1964
Declaration of Helsinki. The study is listed on
http://www.clinicaltrials.gov (NCT00354445). All
study participants provided signed informed
consent.
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Clinical scienceEligible subjects of either gender aged 50 years or older diag-
nosed with subfoveal NV-AMD documented by ﬂuorescein
angiography must have had best-corrected VA of 20/20 to 20/
400 (Snellen) and had one or more but three or less previous
treatments (induction phase) for NV-AMD 30e120 days before
study entry. Subjects had to have shown signiﬁcant improve-
ment of exudative maculopathy after the previous induction
phase based on clinical and/or anatomical ﬁndings, as
determined by the investigator. Although there was no speciﬁc
deﬁnition of clinical improvement, there were two criteria for
anatomical improvement based on optical coherence tomog-
raphy (OCT) assessment: either a centre point thickness (CPT)
of 275 mm or less at study entry or demonstrated retinal thin-
ning of 100 mm or greater occurring between the time of the ﬁrst
induction treatment to study entry. NV-AMD lesions of any
angiographic subtype and 12 or fewer disc areas (including
blood, neovascularisation and scar/atrophy) were entered.
Excluded were the eyes of subjects with subfoveal scarring,
subfoveal atrophy or subfoveal haemorrhage in the study eye
that was 50% or more of the total lesion area or one or more
disc areas; eyes with signiﬁcant media opacities, including
cataract or a history of any intraocular surgery to either eye
within 3 months of trial entry; and a history of posterior
vitrectomy, glaucoma surgery or previous therapeutic radiation
in the region of the study eye. Eyes with pigment epithelial
tears or rips or that had any ocular or periocular infection in
the previous 4 weeks were not enrolled. Subjects with other
causes of choroidal neovascularisation were also excluded.
Additional exclusion criteria included: diabetic retinopathy;
history/evidence of severe cardiac disease, unstable angina,
acute coronary syndrome, myocardial infarction or revascular-
isation within 6 months or ventricular tachyarrhythmias
requiring ongoing treatment; clinically signiﬁcant peripheral
vascular disease or impaired renal or hepatic function;
stroke within the previous 12 months; major surgical procedure
within the previous 1 month; any treatment with an investi-
gational agent in the past 30 days; or known serious allergies to
the ﬂuorescein dye used in angiography or to the components
of pegaptanib sodium. Women of childbearing potential were
required to be using two forms of effective contraception
during the trial and for at least 60 days following the last dose
of test medication.
It is also important to note that we did not, in the study,
include patients who were induced with therapy for wet age-
related macular degeneration (AMD) but then were not shifted
to pegaptanib maintenance therapy. Nor did we include patients
who were not successfully induced with one to three treatments
for wet AMD as per our inclusion criteria.
Figure 1 Mean visual acuity during
induction and maintenance (A) and
mean centre point thickness during
maintenance (B), N¼568.
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Clinical scienceStudy assessments and endpoints
At the baseline visit, which occurred within 7 days before the
ﬁrst pegaptanib injection, a medical and ophthalmological
history (including preinduction VA measurements) and baseline
assessments were conducted. At day 0 (ﬁrst pegaptanib injec-
tion; may have been baseline day) and weeks 6, 12, 18, 24, 30, 36,
42, 48 and 54, refraction and VA measurements (early treatment
diabetic retinopathy scale or Snellen chart) were repeated
preinjection, and tonometry (applanation or Tonopen) and an
ophthalmological examinations were performed both pre and
postinjection. At these visits, tonometry was obtained at least
30 min postinjection. All assessments included both eyes. The
study eye was evaluated using OCT preinjection at weeks 12,
24, 36 and 54, whereas colour fundus photography and ﬂuo-
rescein angiography were performed in both eyes at week 54. At
baseline and all follow-up visits, blood pressure was measured,
concomitant medications were recorded and adverse events were
documented.
Intravitreal pegaptanib 0.3 mg was administered every
6 weeks for 48 weeks with follow-up to week 54. Unscheduled
treatments with other agents used to treat wet AMD were
allowed (booster therapy) at the discretion of the investigator to
counter the deterioration of NV-AMD. Regardless of booster
treatments, subjects continued to receive intravitreal pegaptanib
every 6 weeks unless another anti-VEGF agent was used as
booster treatment in which case the pegaptanib injection was
not required.
No statistical assessments other than descriptive analyses
were prespeciﬁed and no formal power and sample size calcu-
lations were applied. The proportion of subjects maintaining or
gaining vision from baseline to week 54 was nominally consid-
ered the primary efﬁcacy endpoint. Secondary endpoints
included the proportions of subjects gaining one or more, two
and three lines or losing less than three lines of vision at week 54
compared with preinduction, mean VA change from baseline to
week 54 and anatomical outcomes seen on ﬂuorescein angiog-
raphy and OCT. Potential predictors of the need for booster
treatment were also evaluated.
Safety endpoints included all adverse events whether spon-
taneously reported, elicited or observed by investigators. Serious
adverse events were deﬁned as those resulting in death or that
were life-threatening, resulted in hospitalisation, in persistent or
signiﬁcant disability or incapacity or in a congenital anomaly or
birth defect.
The last observation carried forward (LOCF) method was
used to impute missing data. Safety assessments included all
subjects receiving one or more dose of pegaptanib.
RESULTS
The LEVEL study began enrolling subjects in the USA in June
2006. A total of 568 subjects from 87 centres was enrolled, and
487 (86%) completed 1 year of pegaptanib maintenance.
Subjects were elderly (mean age 78.467.6 years), the majority
were women (338; 60%), 57 (10%) were active smokers and 550
(97%) were white. Most subjects had at least one preexisting
condition, the most common of which were vascular disorders,
reported by 433 (76%) subjects, and musculoskeletal/connective
tissue disorders, reported by 347 (61%) subjects. With regard to
induction, 240 (42%) received induction with ranibizumab, 207
(36%) with bevacizumab, 12 (2%) with other single agents
and 108 (19%) with multiple agents, including different
Figure 2 No predictors for booster
treatments at baseline, N¼568. OCT,
optical coherence tomography.
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Table 1 Ocular adverse events*
Serious ocular adverse event No of subjects % Per injection
Endophthalmitis 2y 0.05%
Vitreous haemorrhage 2 0.05%
Conjunctival irritation 1 0.02%
Retinal haemorrhage 1 0.02%
Retinal tear 1 0.02%
Vitreous opacities 1 0.02%
Ocular adverse events reported in $5% of study eyes, N (%)
Punctate keratitis 73 (12.9)
Eye pain 61 (10.7)
Vitreous ﬂoaters 57 (10.0)
Conjunctival haemorrhage 36 (6.3)
Eye irritation 34 (6.0)
Visual acuity reduced 31 (5.5)
Macular degeneration 28 (4.9)
*N¼568 subjects with 4254 total injections.
yOne case was a ‘possible’ endophthalmitis.
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Clinical sciencecombinations of pegaptanib, ranibizumab, bevacizumab,
photodynamic therapy, corticosteroids and transpupillary ther-
motherapy (data are not available for one subject). Subjects
received a mean of 2.6 induction treatments over a median of
15 weeks. Lesions were relatively dry postinduction: the mean
CPT was 191653 mm, 361 (64%) had a CPT of 200 mm or less
and only 119 (21%) had a thickness greater than 225 mm. A
mean of eight injections was administered during the study, and
360/568 (63%) subjects received the maximum of nine pegap-
tanib injections.
Mean VA improved during induction from 49.6621.9 letters
to 65.5615.3 letters and was relatively well preserved during
maintenance (61.8618.9 letters at week 54; ﬁgure 1A; LOCF).
Preinduction to week 54, 444 (79%), 372 (66%), 290 (52%) and
233 (41%) subjects gained none or more, ﬁve or more, 10 or more
and 15 or more letters of VA, respectively; 520 (92%) lost less
than 15 letters. (Note that preinduction VA data were unavail-
able for ﬁve subjects who were excluded from these analyses.)
Mean VA using observed data (not LOCF data) also improved
from baseline to induction (49.6621.9 letters to 65.6615.1
letters, respectively) and was 61.7618.9 letters at week 54.
Median VA showed a similar improvement during induction
(55e69 letters) and was 66 letters at week 54. Fifteen per cent of
subjects (88/568) had VA assessed with Snellen charts. Excluding
those subjects provided similar results on mean VA change over
time compared with the overall study population. VA response
during pegaptanib maintenance was similar in subjects stratiﬁed
by induction anti-VEGF agent (bevacizumab vs ranibizumab);
best 50% versus worst 50% preinduction VA; postinduction VA;
postinduction CPT; and one or more letter versus 10 or more
letter improvement postinduction. Mean CPTwas stable during
pegaptanib maintenance (ﬁgure 1B).
Approximately half the subjects (285/568) did not receive
booster treatment to week 54. Of the 283 subjects receiving
booster treatment, 46% (130/283) required only one such
treatment. Among boosted subjects, the mean time between
the onset of maintenance therapy and ﬁrst booster was
147692 days. Neither number of induction treatments, prein-
duction or baseline VA, nor baseline CPT predicted the need for
booster treatment (ﬁgure 2).
Pegaptanib was safe and well tolerated. A total of 468 (82%)
subjects reported one or more adverse event, 350 (62%) experi-
enced an ocular adverse event and 112 (20%) had one or more
serious adverse event. During 1 year of follow-up, there was no
Figure 3 Mean intraocular pressure
(A) and mean systolic and diastolic
blood pressures (B).
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Clinical scienceevidence of an increased risk of endophthalmitis, retinal
detachment or traumatic cataract when compared with histor-
ical data (table 1).
8 In all, 54% (304/568) of subjects reported
an ocular adverse event; those reported in 5% or more of study
eyes as well as serious ocular adverse events are summarised in
table 1. Intraocular pressure was stable across visits both pre and
postinjection (ﬁgure 3A).
Reports of serious vascular events were rare (table 2). Using
the Anti-Platelet Trialists’ Collaboration classiﬁcation, there
were six (1.1%) cardiovascular deaths, ﬁve (0.9%) non-fatal
myocardial infarctions and three (0.5%) non-fatal cerebrovas-
cular accidents. These rates are similar to those observed in the
VEGF Inhibition Study in Ocular Neovascularization (VISION)
trials’ pegaptanib 0.3 mg group at 1 year (Pﬁzer Inc, data on ﬁle).
Minor infections and infestations were the most frequently
reported non-ocular adverse events (table 2). Mean systolic and
diastolic blood pressures were stable across visits (ﬁgure 3B).
DISCUSSION
The underlying objective of this study was to explore outcomes
obtained by combining the safety record of pegaptanib, now
validated over 4 years in the continuation of the VISION trials,
9
after visual gains were obtained during an induction phase. This
approach, previously studied in relatively small numbers of
patients,
11 12 has now been supported on a larger scale, with
overall visual outcomes including a mean VA improvement of
12.2 letters at 1 year and 41% of patients gaining three or more
early treatment diabetic retinopathy scale lines. Herein, VA gains
were provided by the induction therapy, with pegaptanib
playing a long-term maintenance role; only half of the patients
required a booster treatment, which was given an average of
5 months postbaseline. Anatomical responses, as assessed by
OCT, were similarly maintained. As in the VISION trials,
89
pegaptanib was well tolerated, with few ocular or systemic
events.
Both ocular
13 and systemic
7 adverse effects are potential
safety concerns with VEGF inhibition, although systemic
exposure is likely to be diminished by the higher volume of
distribution. The issue of VEGF-dependent ocular homeostasis
has not been examined clinically, whereas preclinical data
suggest that VEGF plays an essential retinal neuroprotective role
in conditions of ischaemia.
13 In that investigation, the authors
found that only VEGF120, the isoform spared by pegaptanib, was
required for neuroprotection and that sustained inhibition of all
VEGF isoforms led to the progressive loss of retinal ganglion
cells. Another ocular structure for which VEGF is believed
important is the choriocapillaris.
14 Preclinical data suggest that
intravitreal bevacizumab can lead to the loss of choriocapillaris
fenestrations as well as occlusion of the choriocapillaris lumen
by thrombocytes and leucocytes.
15 In addition, recent clinical
data have indicated that the intravitreal injection of ranibi-
zumab can induce vasoconstriction of retinal arterioles in AMD
patients.
16 The authors suggest that this is a downstream effect
of lowered VEGF levels because VEGF has been found to induce
the synthesis of nitric oxide by endothelial cells
17 while reduced
nitric oxide synthesis results in vasoconstriction (reviewed by
Moncada and Higgs).
18
The potential for systemic complications has received more
attention. As discussed in a recent review,
7 the issue of cardio-
vascular risk is especially relevant because the AMD population
is already at higher risk. Moreover, the role of VEGF is especially
complex in the context of atherosclerosis.
19 As VEGF acts to
upregulate the synthesis of tissue factor, the initiator of the
coagulation cascade, inhibition of VEGF could theoretically have
antithrombotic consequences. However, several other mecha-
nisms are likely to promote thromboses in this setting.
19 VEGF
is an endothelial cell survival factor so that inhibition could
favour apoptosis of endothelial cells, leading to their becoming
procoagulant.
20 In addition, VEGF upregulates nitric oxide
synthase and ultimately the production of nitric oxide,
17
a potent anticoagulant. Finally, VEGF has also been reported to
destabilise cholesterol plaques, possibly through the inhibition
of immature blood vessels forming in them.
21 Data suggesting
higher incidences of non-ocular haemorrhage
22 and cerebrovas-
cular accidents
23 in patients receiving a non-selective anti-VEGF
treatment compared with sham injections have been reported.
These ﬁndings indicate that, for some fraction of NV-AMD
patients, minimising exposure to non-selective inhibition is
desirable, especially in the setting of this chronic disease that
requires treatment for many years. Attempts to maintain the
efﬁcacy results obtained with monthly injections of ranibi-
zumab with less frequent dosing have been made with incon-
sistent results,
24 25 suggesting that the regular/frequent
administration of VEGF inhibitors is necessary to optimise
visual outcomes.
In conclusion, the data from this large exploratory study
suggest that maintenance therapy with pegaptanib may provide
an alternative to prolonged non-selective VEGF inhibition by
holding visual gains after induction. As current evidence
supports the long-term use of anti-VEGF agents, induction-
maintenance using non-selective followed by selective VEGF
inhibitors should be considered for the treatment of NV-AMD.
Such an approach has special relevance for patients with
cardiovascular comorbidities who require anti-VEGF drugs to
manage their NV-AMD. Further study is warranted to conﬁrm
these data in broader settings and to reﬁne protocols with a view
to minimising the number of treatments required. In addition,
we also caution the reader to avoid direct comparisons of the
LEVEL trial results with those of other published trials. For
instance, in several anti-VEGF studies, the study design included
continued monthly injections even if the ﬁrst 3 months of
Table 2 Non-ocular adverse events*
Serious non-ocular adverse event N (%)
All nervous system 13 (2.3)
Cerebrovascular accident 3 (0.5)
Cerebral infarction 1 (0.2)
All cardiac 30 (5.3)
Myocardial infarction 4 (0.7)
Acute coronary syndrome 1 (0.2)
Coronary artery occlusion 1 (0.2)
Myocardial ischaemia 1 (0.2)
All non-ocular haemorrhagic 2 (0.4)
Haematuria 1 (0.2)
Other non-ocular adverse events reported in over 2% of subjects
Hypertension 43 (7.6)
Urinary tract infection 26 (4.6)
Sinusitis 25 (4.4)
Gastro-oesophageal reﬂux 21 (3.7)
Pneumonia 20 (3.5)
Benign prostatic hyperplasia 10 (4.3)y
Cardiac failure, congestive 18 (3.2)
Bronchitis 19 (3.3)
Nasopharyngitis 16 (2.8)
Headache 16 (2.8)
Nausea 15 (2.6)
*N¼568 subjects with 4254 total injections.
yConsidering only male study population.
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Clinical sciencetherapy appeared unsuccessful. We do not know how such
initial non-responders would fare with LEVEL trial-type treat-
ment, as they were excluded from entry. We do conclude that
LEVEL trial-type therapy appears to be a viable option for
patients who respond initially to induction therapy and provides
an additional practical treatment option for such individuals
with wet AMD.
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